AINMF
Netramark (NetraAI) provides AI-powered insights to optimize clinical trial design. Their platform deciphers hidden patient correlations and causal factors in trial data, enabling smarter inclusion/exclusion criteria, larger effect sizes, and reduced trial risk. They emphasize patient-centric protocols, enrichment strategies, and decision support for phase III outcomes, leveraging advanced AI methods such as Attractor AI to improve understanding of disease subpopulations. The company operates from Toronto, Canada, and positions itself in the biotech research and healthcare analytics space.
No recent news for this company.
No recent deals for this company.